Home > Boards > US OTC > Miscellaneous > Therapeutic Solutions International, Inc. (TSOI)

27 products total

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
centsability4me Member Profile
Member Level 
Followed By 33
Posts 3,244
Boards Moderated 3
Alias Born 06/17/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:05:22 PM
Therapeutics Solutions International Signs Agreement with Beijing Regenesis Biotechnology InvestorsHub NewsWire - 11/11/2019 9:00:00 AM
Therapeutics Solutions International Reports Augmentation of Rejuvenating Activity of Cord Blood Plasma by Pterostilbene InvestorsHub NewsWire - 11/4/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2019 12:59:28 PM
Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy InvestorsHub NewsWire - 9/9/2019 9:00:00 AM
Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer InvestorsHub NewsWire - 9/3/2019 9:00:00 AM
Therapeutic Solutions International, Inc. Reports Revenues Up 850% for Q2 and 850% for 1st 6 months InvestorsHub NewsWire - 8/29/2019 9:00:00 AM
Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System InvestorsHub NewsWire - 8/26/2019 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2019 4:28:47 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 8/13/2019 1:46:36 PM
Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients InvestorsHub NewsWire - 8/5/2019 9:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 7/30/2019 4:44:49 PM
NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer InvestorsHub NewsWire - 7/29/2019 9:00:00 AM
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Ca... InvestorsHub NewsWire - 7/22/2019 9:00:00 AM
Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release InvestorsHub NewsWire - 7/15/2019 9:00:00 AM
Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of InvestorsHub NewsWire - 7/11/2019 9:00:00 AM
Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product InvestorsHub NewsWire - 7/8/2019 9:00:00 AM
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of InvestorsHub NewsWire - 7/1/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 11:12:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/20/2019 11:18:31 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/14/2019 11:22:33 AM
Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratori... InvestorsHub NewsWire - 5/6/2019 9:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/15/2019 1:36:47 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 3/29/2019 11:33:18 AM
Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation InvestorsHub NewsWire - 2/19/2019 9:00:00 AM
centsability4me Member Level  Sunday, 10/13/19 11:37:29 AM
Re: ADVFN_curncman post# 12495
Post # of 12713 
27 products total
(w/ the additional products distributed in Mexico).
Big Pharma is looking @ the IPs . - the patents , and maybe a future publication in a journal that the oncology community reads.
it requires patience on a different level for shareholders , as the community hurdle is there also.
We are in that waiting period longs . i hope you all will understand the hurdles in Bio-Tech .
We're not @ level 1.0 SEC filings current ,
or 2.0 clinical trials and FDA approval,
but we are @ 3.0 , and now waiting on approval by the oncology community . These are the people that decide which treatments get used - along with the insurers .
NanoStilbene could lower the overall insurance cost if used in combination w/ chemotherapy,
radiotherapy,
and various immunotherapies .

It has to be published first for the oncology community to notice it
Here is the TSOI PR that mentions this :
http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/80602113/therapeutic-solutions-international-announces-posi


August 26, 2019
TSOI) announced today positive results from a pilot clinical trial in advanced cancer patients which have been submitted as a scientific manuscript to a peer reviewed medical journal.

it will get very interesting from here on out ;)
publication & cred from the R and D side of TSOI
IMO

















Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist